US EPA

195866 

Journal Article 

Population distribution of aldehyde dehydrogenase-2 genetic polymorphism: Implications for risk assessment 

Ginsberg, G; Smolenski, S; Hattis, D; Sonawane, B 

2002 

1 

Regulatory Toxicology and Pharmacology
ISSN: 0273-2300
EISSN: 1096-0295 

36 

3 

297-309 

English 

12473414 

10.1006/rtph.2002.1591 

WOS:000179627100008 

https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036929328&doi=10.1006%2frtph.2002.1591&partnerID=40&md5=ea3b921159cbd748aacece5f3666e254
Exit
 

The role of genetic polymorphisms in modulating xenobiotic metabolism and susceptibility to cancer and other health effects has been suggested in numerous studies. However, risk assessments have generally not used this information to characterize population variability or adjust risks for susceptible subgroups. This paper focuses upon the aldehyde dehydrogenase-2 (ALDH2) system because it exemplifies the pivotal role genetic polymorphisms can play in determining enzyme function and susceptibility. Allelic variants in ALDH2 cause decreased ability to clear acetaldehyde and other aldehyde substrates, with homozygous variants (ALDH2*2/2) having no activity and heterozygotes (ALDH2*1/2) having intermediate activity relative to the predominant wild type (ALDH2*1/1). These polymorphisms are associated with increased buildup of acetaldehyde following ethanol ingestion and increased immediate symptoms (flushing syndrome) and long-term cancer risks. We have used Monte Carlo simulation to characterize the population distribution of ALDH2 allelic variants and inter-individual variability in aldehyde internal dose. The nonfunctional allele is rare in most populations, but is common in Asians such that 40% are heterozygotes and 5% are homozygote variants. The ratio of the 95th or 99th percentiles of the Asian population compared to the median of the U.S. population is 14- to 26-fold, a variability factor that is larger than the default pharmacokinetic uncertainty factor (3.2-fold) commonly used in risk assessment. Approaches are described for using ALDH2 population distributions in physiologically based pharmacokinetic?Monte Carlo refinements of risk assessments for xenobiotics which are metabolized to aldehyde intermediates (e.g., ethanol, toluene, ethylene glycol monomethyl ether). 

Acetaldehyde; adverse effects; Aldehyde Dehydrogenase; Asia; Ethanol; genetics; Genetics,Population; Homozygote; Humans; metabolism; Models,Theoretical; Monte Carlo Method; pharmacology; Polymorphism,Genetic; Risk; Risk Assessment; Uncertainty; Xenobiotics; pdf; NRC 2006 document; obtained; Aldehyde Dehydrogenase/genetics/pharmacology; Genetics, Population; Models, Theoretical; Polymorphism, Genetic; Xenobiotics/adverse effects/pharmacology; 0 (Xenobiotics); EC 1.2.1.3 (ALDH2 protein, human); EC 1.2.1.3 (Aldehyde Dehydrogenase)